Travere Therapeutics (TVTX)

Executive Summary

Travere Therapeutics is a biopharmaceutical company focused on developing therapies for rare kidney and metabolic diseases. Its lead product, sparsentan (Filspari), is approved for the treatment of immunoglobulin A nephropathy (IgAN) and has shown strong commercial uptake. The company's pipeline includes sparsentan in focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases, as well as pegtibatinase for homocystinuria (HCU). Sparsentan's Phase 3 PROTECT study in IgAN led to accelerated approval, and the company is pursuing full approval and label expansion. The Phase 3 DUPLEX study in FSGS is expected to read out in 2026, which could significantly expand the addressable market. Pegtibatinase is undergoing a Phase 3 trial (HCCU) with data expected later in 2026, addressing an unmet need in HCU. Travere's commercial infrastructure is established, and the company has a cash runway into 2027. Investor sentiment is positive, driven by sparsentan's sales growth and upcoming catalysts.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 DUPLEX study results for sparsentan in FSGS65% success
• Q4 2026Phase 3 trial results for pegtibatinase in homocystinuria60% success
• Q1 2027FDA decision on sparsentan full approval in IgAN and label expansion80% success